Sight Sciences Raises 2026 Revenue Outlook After Dry-Eye Record

The Tip Desk · November 11, 2026 · 3 min read

The company now expects full-year 2026 revenue of $92 million to $93 million after third-quarter sales of $24.9 million and record Interventional Dry Eye revenue of $3.9 million.

Sight Sciences, Inc. (SGHT), an eyecare technology company, reported record third-quarter revenue of $24.9 million, up 25% from $19.9 million a year earlier, and raised its full-year 2026 revenue outlook.

The year-over-year growth rate accelerated from 20% in the second quarter and 13% in the first quarter. Interventional Dry Eye became the inflection: revenue reached a record $3.9 million, up 45% from $2.7 million in the second quarter, after a 98% sequential increase in the second quarter from $1.4 million in the first quarter. A year earlier, IDE revenue was $0.2 million.

Interventional Glaucoma, still the larger franchise, generated $21.0 million, up 7% from $19.7 million in the third quarter of 2025, after 8% growth in the second quarter and 7% in the first. IG active customers were 1,253, compared with 1,197 a year earlier. IDE lid treatment units sold were 4,581, versus 271 a year earlier, and IDE active customers were 222, versus 50.

Gross profit was $21.4 million. Total gross margin was 86%, in line with the prior-year period. IG gross margin was 87%, also in line. IDE gross margin expanded to 79% from 38% a year earlier.

Net loss narrowed to $6.8 million from $8.2 million a year earlier, a 17% improvement, or $0.12 a share versus $0.16. Total operating expenses were $27.5 million, up 10% from $25.1 million. Research and development expenses were $2.7 million, down 19% from $3.4 million. Selling, general, and administrative expenses were $24.8 million, up 14% from $21.8 million. Adjusted operating expenses were $24.0 million, up 21% from $19.8 million a year earlier.

Cash used in the third quarter was $2.4 million, a 74% decrease from $9.1 million in the third quarter of 2025. Cash and cash equivalents totaled $77.4 million as of September 30, 2026, down from $79.8 million as of June 30. Total debt remained $40.0 million, excluding unamortized discount and debt issuance costs.

The company launched the OMNI Ultra Surgical System at the American Academy of Ophthalmology annual meeting after receiving FDA 510(k) clearance in the second quarter. OMNI Ultra is an expansion of the company’s ab interno canaloplasty platform.

Sight Sciences raised full-year 2026 revenue guidance to $92 million to $93 million, representing year-over-year growth of 19% to 20%, from a prior range of $88 million to $92 million. The new outlook includes Interventional Glaucoma revenue of $80 million to $81 million, representing growth of 6% to 7%, and Interventional Dry Eye revenue of approximately $12 million, compared with a previous range of $9 million to $11 million and $1.6 million in 2025. Full-year 2026 adjusted operating expense guidance was maintained at $92 million to $94 million, an increase of 5% to 7% versus 2025.

Co-Founder and CEO Paul Badawi said the quarter showed 25% total revenue growth, record IDE revenue, continued IG revenue growth, and a significant reduction in cash burn, and that IG is strengthening the foundation while IDE is developing into a meaningful growth driver.